Stocks Health care ADMA
NASDAQ · Health careAdma Biologics, Inc. (ADMA)
Adma Biologics, Inc. brought in $519.2M of revenue over the twelve months to September 30, 2026, up 6.3% from a year earlier. Net income was $182.4M, a net margin of 35.1%. Operating cash flow minus capital spending left $27.8M of free cash flow in fiscal 2025. At September 30, 2026 it held $124.6M in cash against $195.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Adma Biologics, Inc.
- Net worth
- Adma Biologics, Inc. has a market value (market cap) of $2.9B at the latest share price, and shareholders' equity of $438.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $510.2M (+19.6% year on year), with net income of $146.9M. Over the 12 months to September 30, 2026: revenue $519.2M, net income $182.4M.
- Cash flow
- In fiscal 2025 operations brought in $50.4M of cash; after $22.6M of capital spending, free cash flow was $27.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Adma Biologics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Adma Biologics, Inc. does
Adma Biologics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker ADMA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $510.2M | $146.9M | $0.60 | $27.8M |
| 2024 | $426.5M | $197.7M | $0.81 | $110.4M |
| 2023 | $258.2M | -$28.2M | -$0.13 | $4M |
| 2022 | $154.1M | -$65.9M | -$0.33 | -$73.4M |
| 2021 | $80.9M | -$71.6M | -$0.51 | -$125.9M |
| 2020 | $42.2M | -$75.7M | -$0.88 | -$114.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ADMA ranks in Health care
Latest SEC filings
What Adma Biologics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 5.1% to $141.1M versus the same quarter last year; diluted EPS $0.22 versus $0.15.
- November 4, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 2% to $124.4M versus the same quarter last year; diluted EPS $0.16 versus $0.14.
- August 5, 2026
- June 2, 2026
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026Revenue was flat at $114.5M versus the same quarter last year; diluted EPS $0.19 versus $0.11.
- May 6, 2026
- May 4, 2026Other event 8-K
- April 29, 2026Passive stake (5% or more) SCHEDULE 13G
What is ADMA worth? A DCF from its reported cash flow
Insider trades
What the people running Adma Biologics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.8M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 5, 2026 | Grossman Adam SPresident and CEO, Director | Exercised options | 105,000 | $567K |
| November 5, 2026 | Grossman Adam SPresident and CEO, Director | Soldpre-planned (10b5-1) | 105,000 | $1.3M |
| November 5, 2026 | Grossman Adam SPresident and CEO, Director | Soldpre-planned (10b5-1) | 42,000 | $504K |
| July 24, 2026 | Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | Shares withheld for tax | 3,177 | $26.6K |
| July 16, 2026 | Kohler TerryCFO and Treasurer | Received as pay | 85,130 | - |
| May 27, 2026 | Grossman Jerrold BDirector | Bought | 6,400 | $50.6K |
| May 12, 2026 | Grossman Jerrold BDirector | Bought | 12,500 | $100.1K |
| May 11, 2026 | Grossman Jerrold BDirector | Bought | 12,500 | $100.1K |
Who owns ADMA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 5.08% | April 29, 2026 |
Largest institutional holders
Insiders
10 insiders reported holding 6,019,699 shares in total, about $77M at the last price.
| Holder | Shares |
|---|---|
| Elms SteveDirector | 2,143,7502,045,730 held indirectly |
| Grossman Adam SPresident and CEO, Director | 2,070,777 |
| Grossman Jerrold BDirector | 520,284 |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance | 443,061 |
| Kwon YoungDirector | 263,020 |
| Tade Brad L.CFO and Treasurer | 232,940 |
| Kohler TerryCFO and Treasurer | 143,149 |
| Guiheen Lawrence P.Director | 135,52030,000 held indirectly |
| Finger Alison CecilyDirector | 45,619 |
| Salas Eduardo ReneDirector | 21,579 |
Questions about ADMA
What does Adma Biologics, Inc. do?
Adma Biologics, Inc. is a company in the Health care sector, listed on NASDAQ as ADMA. Its shares trade on NASDAQ under the ticker ADMA.
What is Adma Biologics, Inc.'s net worth?
Adma Biologics, Inc. has a market value (market cap) of $2.9B at the latest share price, and shareholders' equity of $438.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Adma Biologics, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $182.4M on revenue of $519.2M, a net margin of 35.1%.
How much revenue does Adma Biologics, Inc. make?
Over the twelve months to September 30, 2026 Adma Biologics, Inc. reported revenue of $519.2M. That is 6.3% more than a year earlier.
When did Adma Biologics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the insider trade from November 5, 2026.
When is Adma Biologics, Inc.'s next earnings report?
Adma Biologics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ADMA with
Follow ADMA
Get an email when Adma Biologics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Adma Biologics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.